Change of Adviser

Evolutec Group PLC
29 January 2007

Monday 29 January 2007





                               Evolutec Group plc

                           ('Evolutec' or 'Company')



                   Appointment of Numis Securities Limited





As previously announced on 3 January 2007, the Board of Evolutec Group plc (AIM:
EVC) is exploring all strategic options available to the Group in order to
realise value for shareholders.



The Board is pleased to announce the appointment, with immediate effect, of
Numis Securities Limited as nominated adviser and broker to assist in this
process.



Shareholders will be kept up to date with developments as appropriate and, in
any event, on announcement of the Annual Results of the Group which is due to
take place on 27 February 2007.





Enquiries:


Evolutec                                                        0118 922 4480
Mark Carnegie Brown, Chief Executive Officer
Nicholas Badman, Chief Financial Officer
www.evolutec.co.uk

Numis                                                           020 7776 1500
Michael Meade

Financial Dynamics                                              020 7831 3113
David Yates
Ben Brewerton





Notes for Editors:



About Evolutec



Evolutec, which is based in Reading, UK, is a clinical stage biopharmaceutical
company with a focus on allergy, inflammation and auto-immune diseases.



rEV576, the Company's second product development candidate is a complement
inhibitor which has demonstrated preclinical activity against the autoimmune
diseases myasthenia gravis and Guillain-Barre Syndrome, asthma and acute
myocardial infarction ('AMI') (heart attack).  Evolutec has established a
research collaboration with Case Western Reserve University, Cleveland, Ohio, to
undertake further preclinical work with rEV576 in myasthenia gravis.



Evolutec is listed on the AIM market of the London Stock Exchange and develops
therapeutics originally isolated from the saliva of ticks.  The tick remains
undetected by its hosts, including humans, by injecting an array of molecules
into the skin that suppresses host immunity.  These stealth molecules have
undergone millions of years of natural evolution to select a promising efficacy,
potency and safety profile. Evolutec employs the tick's evolutionary stealth
technology to offer the potential of treating human diseases.




                      This information is provided by RNS
            The company news service from the London Stock Exchange